Fairmount Funds Management LLC reported 10 positions worth $1.46B for the quarter ended Jun 30, 2026, up 7.1% on the prior quarter. It opened 0 new positions, added to 1, trimmed 0 and exited 1. Its largest holding is Oruka Therapeutics, Inc. at 24.2% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| VRDN Viridian Therapeutics, Inc.\DE | +1.18M | +30.1% | $21.61M | 6.43% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| SYRE Spyre Therapeutics, Inc. | -4.02M | -100.0% | $202.67M | Exited |
No new positions this quarter.
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| SYRE Spyre Therapeutics, Inc. | -4.02M | $202.67M | 14.91% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | ORKA Oruka Therapeutics, Inc. | Healthcare | 3.71M | $352.63M | 24.23% | 0 | 0.0% | Unchanged | 5.89% |
| 2 | DNTH Dianthus Therapeutics, Inc. | Healthcare | 2.54M | $247.33M | 17% | 0 | 0.0% | Unchanged | 4.53% |
| 3 | DMRA Damora Therapeutics, Inc. | Healthcare | 8.71M | $226.63M | 15.57% | 0 | 0.0% | Unchanged | 14.11% |
| 4 | COGT Cogent Biosciences, Inc. | Healthcare | 5.50M | $212.98M | 14.64% | 0 | 0.0% | Unchanged | 3.21% |
| 5 | JBIO Jade Biosciences, Inc. | Healthcare | 4.55M | $101.18M | 6.95% | 0 | 0.0% | Unchanged | 7.16% |
| 6 | ELVN Enliven Therapeutics, Inc. | Healthcare | 1.86M | $94.17M | 6.47% | 0 | 0.0% | Unchanged | 2.53% |
| 7 | VRDN Viridian Therapeutics, Inc.\DE | Healthcare | 5.09M | $93.52M | 6.43% | +1.18M | +30.1% | Added | 4.5% |
| 8 | ZBIO Zenas BioPharma, Inc. | Healthcare | 2.36M | $59.87M | 4.11% | 0 | 0.0% | Unchanged | 3.72% |
| 9 | CBIO Crescent Biopharma, Inc. | Healthcare | 2.75M | $49.46M | 3.4% | 0 | 0.0% | Unchanged | 9% |
| 10 | IKT Inhibikase Therapeutics, Inc. | Healthcare | 8.63M | $17.51M | 1.2% | 0 | 0.0% | Unchanged | 4.94% |
Tip. Select a row to see that position’s full history at Fairmount Funds Management.
As of its Q2 2026 13F filing, Fairmount Funds Management LLC’s five largest positions were Oruka Therapeutics, Inc. (ORKA) at 24.2%, Dianthus Therapeutics, Inc. (DNTH) at 17.0%, Damora Therapeutics, Inc. (DMRA) at 15.6%, Cogent Biosciences, Inc. (COGT) at 14.6%, Jade Biosciences, Inc. (JBIO) at 7.0% of the reported portfolio.
Fairmount Funds Management LLC reported a 13F portfolio worth $1.46B across 10 positions for Q2 2026. That is up 7.1% from the previous quarter.
Its largest purchases by value were Viridian Therapeutics, Inc.\DE ($21.61M). It opened 0 new positions.
Its largest sales by value were Spyre Therapeutics, Inc. ($202.67M). It exited 1 positions entirely.
From the Form 13F-HR reports Fairmount Funds Management LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.